U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 355.300 Ion Generating Devices
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec. 355.300 Ion Generating Devices March 1995

Final
Docket Number:
FDA-2020-D-0957
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health
Office of Regulatory Affairs

BACKGROUND:

There are a number of ion generating devices, both negative and positive, which are being promoted for the treatment of various diseases. When medical claims are made for these ion generating devices, they are subject to the *Federal* Food, Drug, and Cosmetic Act. Until the medical claims can be supported with well controlled and valid scientific studies, these devices are considered misbranded. Should the ion generator produce ozone, it would be subject to 21 CFR 801.415, provided the intended use brings it within the definition of a device. For the most part labeling for ion generators currently being marketed claim the absence of, or very low levels, of ozone production. Truthfulness of such claims require verification.

POLICY:

Ion generating devices promoted for medical use are subject to the requirements of the Federal Food, Drug, and Cosmetic Act. Such devices labeled with unsupported medical claims are in violation of 502(a) and 502(f)(1). If encountered, follow Compliance Policy Guide 7150.10, Health Fraud - Factors in Considering Regulatory Action. *(Please Note: The Health Fraud definition includes the "... promotion, advertisement, distribution or sale of articles, intended for human or animals use ...")*.

*Material between asterisks is new or revised*

Issued: 12/16/74
Reissued: 10/1/80
Revised: 9/24/87, 3/95

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-0957.

Back to Top